In the past two weeks, Procter & Gamble’s near-term call option volume has surged to roughly 120,000 contracts—nearly double the average over the previous month—while put option volume has held steady around 60,000 contracts. This 2:1 call-to-put ratio is the highest recorded since the stock’s mid-year rally and suggests that institutional traders are positioning for a significant upward move. Open interest in the January strike prices has climbed by 35%, indicating that investors are locking in bullish bets well ahead of the company’s fiscal third-quarter report.

Wall Street analysts expect Procter & Gamble to report organic sales growth of approximately 3.5% for the quarter ended December 2025, with core operating margin projected near 23.8%, compared with 24.2% in the prior year period. Consensus forecasting models anticipate adjusted earnings per share of roughly 1.25, a decrease of about 4% year-over-year, driven by continued cost inflation in raw materials and freight. Channel checks suggest inventory levels at major retail partners remain lean, setting the stage for potential upside to these topline assumptions if restocking accelerates in the coming months.

Given the combination of modest volume gains in North America (estimated at +1.8%) and a slight contraction in emerging-market sales (projected –0.5%), Procter & Gamble appears to lack the two key ingredients—above-consensus organic growth and margin expansion—typically associated with an earnings beat. Analysts at three major brokerages currently rate the risk-reward as balanced, highlighting that any downward revision to the core margin forecast or a further slowdown in pricing leverage could pressure consensus EPS estimates, which have already been trimmed by 2 cents over the past three weeks.

Procter & Gamble’s board has formally recommended that shareholders decline an unsolicited mini-tender offer from Potemkin Limited, which seeks to acquire up to 50,000 shares at a price representing about a 31% discount to recent market levels. The company warns that the offer lacks standard investor protections and is subject to multiple contingencies, including an extension option at the bidder’s discretion. Shareholders who have already tendered may withdraw their shares within 14 days of delivery of acceptance documentation, and Procter & Gamble continues to urge investors to consult their financial advisors before making any decisions.